- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Tejas Patil, MD | Authors
CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions: Real-World Implications
July 20, 2022
Looking toward the future management of solid tumors with NRG1 fusions, expert panelists consider how the availability of seribantumab therapy may impact their practice.
Key Takeaways From the CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions
July 14, 2022
A brief review of key takeaways from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.
Duration of Seribantumab Therapy and Depth of Response in the CRESTONE Trial
July 14, 2022
Closing out their review of data from the CRESTONE clinical trial, expert panelists highlight the duration and depth of response with seribantumab therapy.
CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions: Efficacy Data
July 07, 2022
Shared insight on key efficacy data from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.
CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions: Trial Design and Safety Data
July 07, 2022
Expert perspectives on the trial design of and safety data from CRESTONE, which analyzed seribantumab therapy in solid tumors with NRG1 fusions.
Complications of Androgen Deprivation Therapy in Men With Prostate Cancer
September 18, 2018
This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.